<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">WJNS</journal-id><journal-title-group><journal-title>World Journal of Neuroscience</journal-title></journal-title-group><issn pub-type="epub">2162-2000</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/wjns.2021.111007</article-id><article-id pub-id-type="publisher-id">WJNS-107411</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biomedical&amp;Life Sciences</subject></subj-group></article-categories><title-group><article-title>
 
 
  Identification of Secondary Structure of Extracellular Signal Regulated Kinase (ERK) Interacting Proteins and Their Domain: An in Silico Study
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kurrey</surname><given-names>Khuleshwari</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Paramanik</surname><given-names>Vijay</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Cellular and Molecular Neurobiology &amp;amp; Drug Targeting Laboratory, Department of Zoology, Indira Gandhi National Tribal University, Amarkantak (MP), (MP)-484 887, India</addr-line></aff><pub-date pub-type="epub"><day>29</day><month>01</month><year>2021</year></pub-date><volume>11</volume><issue>01</issue><fpage>67</fpage><lpage>89</lpage><history><date date-type="received"><day>29,</day>	<month>November</month>	<year>2020</year></date><date date-type="rev-recd"><day>23,</day>	<month>February</month>	<year>2021</year>	</date><date date-type="accepted"><day>26,</day>	<month>February</month>	<year>2021</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  ERK is involved in multiple cell signaling pathways through its interacting proteins. By 
  in 
  silico
   analysis, earlier we have identified 22 putative ERK interacting proteins namely; ephrin type-B receptor 2 isoform 2 precursor (EPHB2), mitogen-activated protein kinase 1
   
  (MAPK1), interleukin-17 receptor D precursor (IL17RD), WD repeat domain containing 83 (WDR83), tescalcin (Tesc), mitogen-activated protein kinase kinase kinase 4 (MAPP3K4), kinase suppressor of Ras2 (KSR2), mitogen-activated protein kinase kinase 6 (MAP3K6), UL16 binding protein 2 (ULBP2), UL16 binding protein 1 (ULBP1), dual specificity phosphatase 14 (DUSP14), dual specificity phosphatase 6 (DUSP6), hyaluronan-mediated motility receptor (RHAMM), kinase D interacting substrate of 220
   
  kDa (KININS220), membrane-associated guanylate kinase (MAGI3), phosphoprotein enriched in astrocytes 15
   
  (PEA15), typtophenyl-tRNA synthetase, cytoplasmic (WARS), dual specificity phosphatase 9 (DUSP9), mitogen-activated protein kinase kinase kinase 1
   
  (MAP3K1), UL16 binding protein 3 (ULBP3), SLAM family member 7 isoform a precursor (SLAMMF7) and mitogen activated protein kinase kinase kinase 11 (MAP3K11) (
  <b>Table 1</b>
  ). However, prediction of secondary structure and domain/motif present in aforementioned ERK interacting proteins is not studied. In this paper, in
   silico
   prediction of secondary structure of ERK interacting proteins was done by SOPMA and motif/domain identification using motif search. Briefly, SOPMA predicted higher random coil and alpha helix percentage in these proteins (
  <b>Table 2</b>
  )
   and
   motif scan predicted serine/threonine kinases active site signature and protein kinase ATP binding region in majority of ERK interacting proteins. Moreover, few have commonly dual specificity protein phosphatase family and tyrosine specific protein phosphatase domains (
  <b>Table 3</b>
  ). Such study may be helpful to design engineered molecules for regulating ERK dependent pathways in disease condition.
 
</p></abstract><kwd-group><kwd>ERK</kwd><kwd> Secondary Structure</kwd><kwd> Motif Scan</kwd><kwd> Random Coils</kwd><kwd> Alpha Helix</kwd><kwd> Protein Kinases</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Background</title><p>Prediction of protein function is one of the key tasks of bioinformatics. The prediction of protein function is dependent on secondary structure and their amino acid sequence. Further, use of bioinformatics has revealed construction blocks of several proteins in recent years. The construction of 3D protein structure and prediction of biological function is increasing day by day. The region of protein actually interacted and involved in biological function is called domain/motifs. Therefore, prediction of protein structure is highly useful. However, it gives additional trouble to save protein structures and their features based on domain/motifs.</p><p>Usually most of the signaling transduction pathways use protein kinases to phosphorylate target protein by phosphorylation process. However, how protein kinases are able to achieve specificity needed to control several cellular functions remains a significant question [<xref ref-type="bibr" rid="scirp.107411-ref1">1</xref>]. Nonetheless, many distinct stimuli can activate the protein kinase cascade which phosphorylates versatile molecule ERK and controls multiple cellular signals [<xref ref-type="bibr" rid="scirp.107411-ref2">2</xref>]. Moreover, it is still uncertain how single ERK molecule is evolved to control comprehensive arrays of cellular and molecular mechanism. One of the possibilities is the recruitment of ERK interacting proteins. After interaction with these proteins, ERK controls array of cellular activity like cell proliferation, cell migration, survival, neuronal growth and neurotransmission. In addition, ERK dependent pathway is influenced by various stimulations such as growth, cytokines, viruses, second messengers, carcinogens and transforming agents [<xref ref-type="bibr" rid="scirp.107411-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.107411-ref4">4</xref>].</p><p>The protein kinases family is huge with lots of variation. However, a very few differ in size, sub cellular distribution and mode of action. The catalytic accuracy of protein kinases is very critical as they work as regulatory molecules for biological functions. Further, domain/motif of a protein serves as actual site of interaction for the manifestation of a specific biological function. Hence prediction of domain/motif or sites of proteins has been done using bioinformatics tools over the past decade. The prediction of domain/motif actually helps researchers to recognize proteins binding sites, secondary structures, 3D structure and building blocks [<xref ref-type="bibr" rid="scirp.107411-ref5">5</xref>]. However, there are only a few techniques which are used for general investigation of significant motifs in protein structures [<xref ref-type="bibr" rid="scirp.107411-ref6">6</xref>].</p><p>A protein attains various conformations to perform diverse functions. Further, different conformations of proteins actually determine possibility of specific motifs leading to several functions. Further, in silico identification of ERK interacting proteins and physicochemical analysis was reported earlier [<xref ref-type="bibr" rid="scirp.107411-ref3">3</xref>] (<xref ref-type="table" rid="table1">Table 1</xref>). These were namely; ephrin type-B receptor 2 isoform 2 precursor (EPHB2), mitogen-activated protein kinase 1 (MAPK1), interleukin-17 receptor D precursor (IL17RD), WD repeat domain containing 83 (WDR83), tescalcin (Tesc), mitogen-activated protein kinase kinase kinase 4 (MAPP3K4), kinase suppressor of Ras2 (KSR2), mitogen-activated protein kinase kinase 6 (MAP3K6), UL16 binding protein 2 (ULBP2), UL16 binding protein 1 (ULBP1), dual specificity phosphatase 14 (DUSP14), dual specificity phosphatase 6 (DUSP6), hyaluronan-mediated motility receptor (RHAMM), kinase D interacting substrate of 220 kDa (KININS220), membrane-associated guanylate kinase (MAGI3), phosphoprotein enriched in astrocytes 15(PEA15), typtophenyl-tRNA synthetase,</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> ERK interacting proteins</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >S. N.</th><th align="center" valign="middle" >NCBI Reference Sequence</th><th align="center" valign="middle" >Gene Name</th><th align="center" valign="middle" >Protein Name</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >NP_004433</td><td align="center" valign="middle" >EPHB2</td><td align="center" valign="middle" >ephrin type-B receptor 2 isoform 2 precursor</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >NP_620407.1</td><td align="center" valign="middle" >MAPK1</td><td align="center" valign="middle" >mitogen-activated protein kinase 1</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >NP_060033.3</td><td align="center" valign="middle" >IL17RD</td><td align="center" valign="middle" >interleukin-17 receptor D precursor</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >NP_001093207.1</td><td align="center" valign="middle" >WDR83</td><td align="center" valign="middle" >WD repeat domain-containing protein 83</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >AAH15221.1</td><td align="center" valign="middle" >TESC</td><td align="center" valign="middle" >tescalcin</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >AAI36277.1</td><td align="center" valign="middle" >MAP3K4</td><td align="center" valign="middle" >mitogen-activated protein kinase kinase kinase 4</td></tr><tr><td align="center" valign="middle" >7</td><td align="center" valign="middle" >Q6VAB6.2</td><td align="center" valign="middle" >KSR2</td><td align="center" valign="middle" >Kinase suppressor of Ras 2</td></tr><tr><td align="center" valign="middle" >8</td><td align="center" valign="middle" >EAX07758.1</td><td align="center" valign="middle" >MAP3K6</td><td align="center" valign="middle" >mitogen-activated protein kinase kinase kinase 6</td></tr><tr><td align="center" valign="middle" >9</td><td align="center" valign="middle" >AAQ89028.1</td><td align="center" valign="middle" >ULBP2</td><td align="center" valign="middle" >UL16 binding protein 2</td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >AAK13081.1</td><td align="center" valign="middle" >ULBP1</td><td align="center" valign="middle" >UL16 binding protein 1</td></tr><tr><td align="center" valign="middle" >11</td><td align="center" valign="middle" >CAG38739.1</td><td align="center" valign="middle" >DUSP14</td><td align="center" valign="middle" >dual specificity phosphatase 14</td></tr><tr><td align="center" valign="middle" >12</td><td align="center" valign="middle" >BAA34369.1</td><td align="center" valign="middle" >DUSP6</td><td align="center" valign="middle" >dual specificity phosphatase 6</td></tr><tr><td align="center" valign="middle" >13</td><td align="center" valign="middle" >AAI08905.1</td><td align="center" valign="middle" >RHAMM</td><td align="center" valign="middle" >hyaluronan-mediated motility receptor</td></tr><tr><td align="center" valign="middle" >14</td><td align="center" valign="middle" >NP_065789.1</td><td align="center" valign="middle" >KIDINS220</td><td align="center" valign="middle" >kinase D-interacting substrate of 220 kDa</td></tr><tr><td align="center" valign="middle" >15</td><td align="center" valign="middle" >NP_001136254.1</td><td align="center" valign="middle" >MAGI3</td><td align="center" valign="middle" >membrane-associated guanylate kinase</td></tr><tr><td align="center" valign="middle" >16</td><td align="center" valign="middle" >CAG46533.1</td><td align="center" valign="middle" >PEA15</td><td align="center" valign="middle" >phosphoprotein enriched in astrocytes 15</td></tr><tr><td align="center" valign="middle" >17</td><td align="center" valign="middle" >AAH95453.1</td><td align="center" valign="middle" >WARS</td><td align="center" valign="middle" >tryptophanyl-tRNA synthetase, cytoplasmic</td></tr><tr><td align="center" valign="middle" >18</td><td align="center" valign="middle" >AAH60837.1</td><td align="center" valign="middle" >DUSP9</td><td align="center" valign="middle" >dual specificity phosphatase 9</td></tr><tr><td align="center" valign="middle" >19</td><td align="center" valign="middle" >NP_005912.1</td><td align="center" valign="middle" >MAP3K1</td><td align="center" valign="middle" >mitogen-activated protein kinase kinase kinase 1</td></tr><tr><td align="center" valign="middle" >20</td><td align="center" valign="middle" >AAK13083.1</td><td align="center" valign="middle" >ULBP3</td><td align="center" valign="middle" >UL16 binding protein 3</td></tr><tr><td align="center" valign="middle" >21</td><td align="center" valign="middle" >NP_067004.3</td><td align="center" valign="middle" >SLAMF7</td><td align="center" valign="middle" >SLAM family member 7 isoform a precursor</td></tr><tr><td align="center" valign="middle" >22</td><td align="center" valign="middle" >NP_002410.1</td><td align="center" valign="middle" >MAP3K11</td><td align="center" valign="middle" >mitogen-activated protein kinase kinase kinase 11</td></tr></tbody></table></table-wrap><p>cytoplasmic (WARS), dual specificity phosphatase 9 (DUSP9), mitogen-activated protein kinase kinase kinase 1 (MAP3K1), UL16 binding protein 3 (ULBP3), SLAM family member 7 isoform a precursor (SLAMMF7) and mitogen activated protein kinase kinase kinase 11 (MAP3K11). Majority of these are kinase and interact with ERK. Hence, they may contain similar secondary structures and domain/motifs. Moreover, no study of secondary structure and domain/motif is available about ERK interacting proteins. Hence, it promotes us to identify secondary structure and prediction of domain/motif of ERK interacting proteins using in silico. Such studies are useful to understand ERK dependent pathways and helpful to design engineered molecules for regulating them in disease situation.</p></sec><sec id="s2"><title>2. Materials and Methods</title><p>For identification of secondary structure of ERK interacting proteins were retrieved in earlier study (<xref ref-type="table" rid="table1">Table 1</xref>) [<xref ref-type="bibr" rid="scirp.107411-ref3">3</xref>]. Thereafter, secondary structure of these protein were done by Self-Optimized Prediction Method with Alignment (SOPMA) (https://npsa-prabi.ibcp.fr/NPSA/npsa_sopma.html) using aa sequence of protein in FASTA format (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><p>For identification of domain/motif search among ERK interacting protein, motif search, (https://www.genome.jp/tools/motif) a computer-based database was used. There is a choice of computer-based application available for identification of motifs. These were most frequently characterized by a single function namely prediction of phosphorylation sites [<xref ref-type="bibr" rid="scirp.107411-ref7">7</xref>]. In this paper, PROSITE was used for documentation of motif and domain of proteins. PROSITE is an annotated collection of protein families and domains classifying motif descriptors. PROSITE's motif descriptors are either prosite patterns (ProPat) or prosite profiles (ProPro) received from various alignments of homologous sequences. ProPat are descriptors of qualitative motifs. As the sequence</p><p>of biologically significant motifs is evolutionarily preserved, a multiple alignment of them can be decreased to an expression of agreement called regular expression or pattern. Every location of such a pattern can be taken up by any residue from a given set of acceptable substances, and a variable number of times within a specified spectrum for variable number of times within a specified spectrum. In addition, ProPro is a quantitative protein domain demonstration. ProPat is more complicated. Usually the ProPro corresponds with the protein domain [<xref ref-type="bibr" rid="scirp.107411-ref8">8</xref>].</p></sec><sec id="s3"><title>3. Results and Discussion</title><p>In this study, out of 22 ERK interacting proteins; 12 proteins namely; EPHB2, MAPK1, WDR83, TESC, MAP3K4, DUSP14, KSR2, MAP3K6, MAGI3, WARS, MAP3K1 and MAP3K11 showed both ProPat and ProPro. The highest number of ProPat was found in EPHB2. Further, 6 proteins namely; IL17RD, DUSP6, KIDINS220, PEA15, DUSP9 and SLAMF7 interacting proteins showed only ProPro. However, remaining 4 ERK interacting proteins namely; ULBP2, ULBP1, RHAMM and ULBP3 do not show both ProPat and ProPro. Among above mentioned 12 proteins, 6 interacting proteins viz, MAPK1, MAP3K4, KSR2, MAP3K6, MAP3K1 and MAP3K11 showed serine/threonine kinases active site signature and protein kinase ATP binding region signature domain commonly in their pattern whereas remaining namely EPHB2, WDR83, TESC, DUSP14, MAGI3 and WARS showed different protein kinase protein family domain pattern. In addition, in case of ProPro 7 proteins namely; EPHB2, MAPK1, MAP3K4, KSR2, MAP3K6, MAP3K1 and MAP3K11, indicated protein kinase domain profile commonly and other 3 proteins namely; DUSP9, DUSP14 and DUSP6 represented commonly dual specificity protein phosphatase family profile and tyrosine specific protein phosphatase family profile. The details of ProPat and Pro Pro are listed in <xref ref-type="table" rid="table3">Table 3</xref> and Figures 1-10 (Supplementary materials).</p><p>The secondary structure of 22 ERK interacting are mentioned in <xref ref-type="table" rid="table2">Table 2</xref> and Figures 11-32 (Supplementary materials). Out of 22 ERK interacting proteins 12 proteins namely; EPHB2, IL17RD, KSR2, ULBP1, DUSP6, KIDINS220, MAGI3, DUSP9, MAP3K1, SLAMF7, MAP3K11 showed higher % of random coil. Interestingly, when the dimensions of a number of proteins are compared, variations in the population of residual structure in the denatured state leads to deviations from ideal random coil behavior [<xref ref-type="bibr" rid="scirp.107411-ref9">9</xref>]. Moreover, these types of proteins do not attain conformational changes like secondary structure, tertiary structure and any other conformations [<xref ref-type="bibr" rid="scirp.107411-ref3">3</xref>]. Usually, in this situation, protein structure has been detectable in multidimensional magnetic resonance which depends on particular peptide-peptide communication. Likewise, parts of random coil appear merely</p><table-wrap-group id="2"><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Secondary structure data of ERK interacting proteins</title></caption><table-wrap id="2_1"><table><tbody><thead><tr><th align="center" valign="middle" >1. Ephrin type-B receptor 2 isoform 2 precursor</th><th align="center" valign="middle" >Alpha helix (Hh): 250 is 25.33% 310 helix (Gg): 0 is 0.00% Pi helix (Ii): 0 is 0.00% Beta bridge (Bb): 0 is 0.00% Extended strand (Ee): 211 is 21.38% Beta turn (Tt): 54 is 5.47% Bend region (Ss): 0 is 0.00% Random coil (Cc): 472 is 47.82% Ambiguous states (?): 0 is 0.00% Other states: 0 is 0.00%</th></tr></thead><tr><td align="center" valign="middle" >2. Mitogen-activated protein kinase 1</td><td align="center" valign="middle" >Alpha helix (Hh): 178 is 49.44% 310 helix (Gg): 0 is 0.00% Pi helix (Ii): 0 is 0.00% Beta bridge (Bb): 0 is 0.00% Extended strand (Ee): 47 is 13.06% Beta turn (Tt): 24 is 6.67% Bend region (Ss): 0 is 0.00% Random coil (Cc): 111 is 30.83% Ambiguous states (?): 0 is 0.00% Other states: 0 is 0.00%</td></tr><tr><td align="center" valign="middle" >3. Interleukin-17 receptor D precursor</td><td align="center" valign="middle" >Alpha helix (Hh): 223 is 30.18% 310 helix (Gg): 0 is 0.00% Pi helix (Ii): 0 is 0.00% Beta bridge (Bb): 0 is 0.00% Extended strand (Ee): 136 is 18.40% Beta turn (Tt): 40 is 5.41% Bend region (Ss): 0 is 0.00% Random coil (Cc): 340 is 46.01% Ambiguous states (?): 0 is 0.00% Other states: 0 is 0.00%</td></tr><tr><td align="center" valign="middle" >4. WD repeat domain-containing protein 83</td><td align="center" valign="middle" >Alpha helix (Hh): 34 is 10.79% 310 helix (Gg): 0 is 0.00% Pi helix (Ii): 0 is 0.00% Beta bridge (Bb): 0 is 0.00% Extended strand (Ee): 125 is 39.68% Beta turn (Tt): 43 is 13.65% Bend region (Ss): 0 is 0.00% Random coil (Cc): 113 is 35.87% Ambiguous states (?): 0 is 0.00% Other states: 0 is 0.00%</td></tr><tr><td align="center" valign="middle" >5. Tescalcin</td><td align="center" valign="middle" >Alpha helix (Hh): 133 is 62.15% 310 helix (Gg): 0 is 0.00% Pi helix (Ii): 0 is 0.00% Beta bridge (Bb): 0 is 0.00% Extended strand (Ee): 11 is 5.14% Beta turn (Tt): 7 is 3.27% Bend region (Ss): 0 is 0.00% Random coil (Cc): 63 is 29.44% Ambiguous states (?): 0 is 0.00% Other states: 0 is 0.00%</td></tr></tbody></table></table-wrap><table-wrap id="2_2"><table><tbody><thead><tr><th align="center" valign="middle" >6. Mitogen-activated protein kinase kinasekinase 4</th><th align="center" valign="middle" >Alpha helix (Hh): 756 is 47.01% 310 helix (Gg): 0 is 0.00% Pi helix (Ii): 0 is 0.00% Beta bridge (Bb): 0 is 0.00% Extended strand (Ee): 143 is 8.89% Beta turn (Tt): 65 is 4.04% Bend region (Ss): 0 is 0.00% Random coil (Cc): 644 is 40.05% Ambiguous states (?): 0 is 0.00% Other states: 0 is 0.00%</th></tr></thead><tr><td align="center" valign="middle" >7. Kinase suppressor of Ras 2</td><td align="center" valign="middle" >Alpha helix (Hh): 254 is 26.74% 310 helix (Gg): 0 is 0.00% Pi helix (Ii): 0 is 0.00% Beta bridge (Bb): 0 is 0.00% Extended strand (Ee): 128 is 13.47% Beta turn (Tt): 54 is 5.68% Bend region (Ss): 0 is 0.00% Random coil (Cc): 514 is 54.11% Ambiguous states (?): 0 is 0.00% Other states: 0 is 0.00%</td></tr><tr><td align="center" valign="middle" >8. Mitogen-activated protein kinase kinasekinase 6</td><td align="center" valign="middle" >Alpha helix (Hh): 534 is 41.46% 310 helix (Gg): 0 is 0.00% Pi helix (Ii): 0 is 0.00% Beta bridge (Bb): 0 is 0.00% Extended strand (Ee): 174 is 13.51% Beta turn (Tt): 63 is 4.89% Bend region (Ss): 0 is 0.00% Random coil (Cc): 517 is 40.14% Ambiguous states (?): 0 is 0.00% Other states: 0 is 0.00%</td></tr><tr><td align="center" valign="middle" >9. UL16 binding protein 2</td><td align="center" valign="middle" >Alpha helix (Hh): 101 is 41.06% 310 helix (Gg): 0 is 0.00% Pi helix (Ii): 0 is 0.00% Beta bridge (Bb): 0 is 0.00% Extended strand (Ee): 38 is 15.45% Beta turn (Tt): 16 is 6.50% Bend region (Ss): 0 is 0.00% Random coil (Cc): 91 is 36.99% Ambiguous states (?): 0 is 0.00% Other states: 0 is 0.00%</td></tr><tr><td align="center" valign="middle" >10. UL16 binding protein 1</td><td align="center" valign="middle" >Alpha helix (Hh): 84 is 34.43% 310 helix (Gg): 0 is 0.00% Pi helix (Ii): 0 is 0.00% Beta bridge (Bb): 0 is 0.00% Extended strand (Ee): 46 is 18.85% Beta turn (Tt): 18 is 7.38% Bend region (Ss): 0 is 0.00% Random coil (Cc): 96 is 39.34% Ambiguous states (?): 0 is 0.00% Other states: 0 is 0.00%</td></tr></tbody></table></table-wrap><table-wrap id="2_3"><table><tbody><thead><tr><th align="center" valign="middle" >11. Dual specificity phosphatase 14</th><th align="center" valign="middle" >Alpha helix (Hh): 73 is 36.87% 310 helix (Gg): 0 is 0.00% Pi helix (Ii): 0 is 0.00% Beta bridge (Bb): 0 is 0.00% Extended strand (Ee): 25 is 12.63% Beta turn (Tt): 10 is 5.05% Bend region (Ss): 0 is 0.00% Random coil (Cc): 90 is 45.45% Ambiguous states (?): 0 is 0.00% Other states: 0 is 0.00%</th></tr></thead><tr><td align="center" valign="middle" >12. Dual specificity phosphatase 6</td><td align="center" valign="middle" >Alpha helix (Hh): 128 is 33.60% 310 helix (Gg): 0 is 0.00% Pi helix (Ii): 0 is 0.00% Beta bridge (Bb): 0 is 0.00% Extended strand (Ee): 59 is 15.49% Beta turn (Tt): 17 is 4.46% Bend region (Ss): 0 is 0.00% Random coil (Cc): 177 is 46.46% Ambiguous states (?): 0 is 0.00% Other states: 0 is 0.00%</td></tr><tr><td align="center" valign="middle" >13. Hyaluronan-mediated motility receptor</td><td align="center" valign="middle" >Alpha helix (Hh): 581 is 80.14% 310 helix (Gg): 0 is 0.00% Pi helix (Ii): 0 is 0.00% Beta bridge (Bb): 0 is 0.00% Extended strand (Ee): 18 is 2.48% Beta turn (Tt): 13 is 1.79% Bend region (Ss): 0 is 0.00% Random coil (Cc): 113 is 15.59% Ambiguous states (?): 0 is 0.00% Other states: 0 is 0.00%</td></tr><tr><td align="center" valign="middle" >14. Kinase D-interacting substrate of 220 kDa</td><td align="center" valign="middle" >Alpha helix (Hh): 680 is 38.40% 310 helix (Gg): 0 is 0.00% Pi helix (Ii): 0 is 0.00% Beta bridge (Bb): 0 is 0.00% Extended strand (Ee): 200 is 11.29% Beta turn (Tt): 98 is 5.53% Bend region (Ss): 0 is 0.00% Random coil (Cc): 793 is 44.78% Ambiguous states (?): 0 is 0.00% Other states: 0 is 0.00%</td></tr><tr><td align="center" valign="middle" >15. Membrane-associated guanylate kinase</td><td align="center" valign="middle" >Alpha helix (Hh): 223 is 15.06% 310 helix (Gg): 0 is 0.00% Pi helix (Ii): 0 is 0.00% Beta bridge (Bb): 0 is 0.00% Extended strand (Ee): 229 is 15.46% Beta turn (Tt): 88 is 5.94% Bend region (Ss): 0 is 0.00% Random coil (Cc): 941 is 63.54% Ambiguous states (?): 0 is 0.00% Other states: 0 is 0.00%</td></tr></tbody></table></table-wrap><table-wrap id="2_4"><table><tbody><thead><tr><th align="center" valign="middle" >16. Phosphoprotein enriched in astrocytes 15</th><th align="center" valign="middle" >Alpha helix (Hh): 75 is 57.69% 310 helix (Gg): 0 is 0.00% Pi helix (Ii): 0 is 0.00% Beta bridge (Bb): 0 is 0.00% Extended strand (Ee): 8 is 6.15% Beta turn (Tt): 3 is 2.31% Bend region (Ss): 0 is 0.00% Random coil (Cc): 44 is 33.85% Ambiguous states (?): 0 is 0.00% Other states: 0 is 0.00%</th></tr></thead><tr><td align="center" valign="middle" >17. Tryptophanyl-tRNA synthetase, cytoplasmic</td><td align="center" valign="middle" >Alpha helix (Hh): 207 is 43.95% 310 helix (Gg): 0 is 0.00% Pi helix (Ii): 0 is 0.00% Beta bridge (Bb): 0 is 0.00% Extended strand (Ee): 48 is 10.19% Beta turn (Tt): 28 is 5.94% Bend region (Ss): 0 is 0.00% Random coil (Cc): 188 is 39.92% Ambiguous states (?): 0 is 0.00% Other states: 0 is 0.00%</td></tr><tr><td align="center" valign="middle" >18. Dual specificity phosphatase 9</td><td align="center" valign="middle" >Alpha helix (Hh): 132 is 34.38% 310 helix (Gg): 0 is 0.00% Pi helix (Ii): 0 is 0.00% Beta bridge (Bb): 0 is 0.00% Extended strand (Ee): 55 is 14.32% Beta turn (Tt): 26 is 6.77% Bend region (Ss): 0 is 0.00% Random coil (Cc): 171 is 44.53% Ambiguous states (?): 0 is 0.00% Other states: 0 is 0.00%</td></tr><tr><td align="center" valign="middle" >19. Mitogen-activated protein kinase kinasekinase 1</td><td align="center" valign="middle" >Alpha helix (Hh): 538 is 35.58% 310 helix (Gg): 0 is 0.00% Pi helix (Ii): 0 is 0.00% Beta bridge (Bb): 0 is 0.00% Extended strand (Ee): 156 is 10.32% Beta turn (Tt): 66 is 4.37% Bend region (Ss): 0 is 0.00% Random coil (Cc): 752 is 49.74% Ambiguous states (?): 0 is 0.00% Other states: 0 is 0.00%</td></tr><tr><td align="center" valign="middle" >20. UL16 binding protein 3</td><td align="center" valign="middle" >Alpha helix (Hh): 88 is 36.07% 310 helix (Gg): 0 is 0.00% Pi helix (Ii): 0 is 0.00% Beta bridge (Bb): 0 is 0.00% Extended strand (Ee): 51 is 20.90% Beta turn (Tt): 18 is 7.38% Bend region (Ss): 0 is 0.00% Random coil (Cc): 87 is 35.66% Ambiguous states (?): 0 is 0.00% Other states: 0 is 0.00%</td></tr></tbody></table></table-wrap><table-wrap id="2_5"><table><tbody><thead><tr><th align="center" valign="middle" >21. SLAM family member 7 isoform a precursor</th><th align="center" valign="middle" >Alpha helix (Hh): 68 is 20.30% 310 helix (Gg): 0 is 0.00% Pi helix (Ii): 0 is 0.00% Beta bridge (Bb): 0 is 0.00% Extended strand (Ee): 87 is 25.97% Beta turn (Tt): 13 is 3.88% Bend region (Ss): 0 is 0.00% Random coil (Cc): 167 is 49.85% Ambiguous states (?): 0 is 0.00% Other states: 0 is 0.00%</th></tr></thead><tr><td align="center" valign="middle" >22. Mitogen-activated protein kinase kinasekinase 11</td><td align="center" valign="middle" >Alpha helix (Hh): 229 is 27.04% 310 helix (Gg): 0 is 0.00% Pi helix (Ii): 0 is 0.00% Beta bridge (Bb): 0 is 0.00% Extended strand (Ee): 106 is 12.51% Beta turn (Tt): 39 is 4.60% Bend region (Ss): 0 is 0.00% Random coil (Cc): 473 is 55.84% Ambiguous states (?): 0 is 0.00% Other states: 0 is 0.00%</td></tr></tbody></table></table-wrap></table-wrap-group><p>as a lack of “electron density” or contrast in the pictures generated in crystallography experiments. Circular dichroism is used to distinguish random coils. Moreover, the complete denaturation of protein lowers the percentage of random coil. We found that ERK interacting proteins were rich in random coil and alpha helix. Hence, ERK interacting proteins are not denatured and may perform various functions [<xref ref-type="bibr" rid="scirp.107411-ref3">3</xref>]. Moreover, 9 proteins namely MAPK1, TESC, MAP3K4, MAP3K6, ULBP2, RHAMM, WARS, ULBP3, PEA15, showed high percentage of alpha helix and WDR83 showed extended strand.</p><p>Long-term synaptic plasticity is the consequence of multiple gene expressions. ERK is one of those genes engaged in long-term memory and learning. A cascade of regulative genes has been recruited to particular genes including ERK in the process of long-term learning and memory formation [<xref ref-type="bibr" rid="scirp.107411-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.107411-ref11">11</xref>]. Moreover, chromatin remodeling is decisive for expression of genes [<xref ref-type="bibr" rid="scirp.107411-ref12">12</xref>]. ERK has been found to interact with a host of proteins to perform various cellular functions. Therefore, these proteins are important and involved in several diseases/disorders associated to the brain. Further, ERK interacting proteins have been reported to contain higher percentage of hydrophobic amino acid leucine [<xref ref-type="bibr" rid="scirp.107411-ref3">3</xref>].</p><p>Additionally, leucine works as an mTOR activator. mTOR also known as a mammalian target of rapamycin and FK 506-binding protein 12 rapamycin-associated protein 1 (FRAP1). FRAP1 is a kinase and encoded by the mTOR gene. mTOR links with other proteins and serves as a core component of two distinct protein complexes, mTOR complex 1 and mTOR complex 2. These both complexes work as a serine/threonine protein kinase. Being a core component of mTORC 2, mTOR works as a tyrosine protein kinase and promotes activation of insulin receptors as well as insulin like growth factor 1 receptors. In addition, mTOR modulates cell growth, proliferation and neuronal plasticity through protein synthesis regulation [<xref ref-type="bibr" rid="scirp.107411-ref13">13</xref>]. Specifically, mTOR controls the translation of a small segment of mRNAs containing a large secondary structure at their 5' UTR or oligopyrimidine at their 5' ends (TOP mRNAs) [<xref ref-type="bibr" rid="scirp.107411-ref14">14</xref>] [<xref ref-type="bibr" rid="scirp.107411-ref15">15</xref>]. This kinase can be triggered by distinct extracellular signals and controls protein synthesis at initiation stage primarily by phosphorylation of at least two downstream targets mainly p70S6 kinase (p70S6 K) and eukaryotic initiation factor 4E-binding proteins [<xref ref-type="bibr" rid="scirp.107411-ref16">16</xref>].</p><p>In neurons, mTOR has been reported in the synaptic region and mediates synthesis of locally-translated proteins. Also, mTOR is up-regulated in an activity dependent manner and critical for different forms of synaptic plasticity including long-term potentiation (LTP) [<xref ref-type="bibr" rid="scirp.107411-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.107411-ref18">18</xref>]. Nonetheless, little is known about the extracellular signals activated by training and trigger mTOR for protein synthesis regulation during memory consolidation. However, mTOR is required for memory formation in many learning tasks [<xref ref-type="bibr" rid="scirp.107411-ref19">19</xref>] [<xref ref-type="bibr" rid="scirp.107411-ref20">20</xref>]. BDNF induces rapamycin-sensitive synaptic potentiation [<xref ref-type="bibr" rid="scirp.107411-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.107411-ref17">17</xref>] and regulates translation of 5' TOP mRNA encoded proteins at dendrites through an mTOR-dependent pathway [<xref ref-type="bibr" rid="scirp.107411-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.107411-ref19">19</xref>] [<xref ref-type="bibr" rid="scirp.107411-ref21">21</xref>] [<xref ref-type="bibr" rid="scirp.107411-ref22">22</xref>]. Taken together, it can be concluded that leucine rich food supplement can be helpful for learning and memory.</p><p>In addition, ERK interacting proteins showed higher serine/threonine kinases active site signature and protein kinase ATP binding region signature domain commonly in ProPat. They showed protein kinase domain, dual specificity protein phosphatase and tyrosine specific protein phosphatase family domain in ProPro. Several studies have suggested that learning and memory are mediated by neuronal plasticity, strengthening of LTP [<xref ref-type="bibr" rid="scirp.107411-ref23">23</xref>], synaptogenesis [<xref ref-type="bibr" rid="scirp.107411-ref24">24</xref>], modulation of intrinsic excitability [<xref ref-type="bibr" rid="scirp.107411-ref25">25</xref>] and adult neurogenesis [<xref ref-type="bibr" rid="scirp.107411-ref26">26</xref>]. All the above-mentioned processes may require protein kinases (enzymes that transfer phosphate groups to side chains of particular amino acids (serine/threonine or tyrosine) of target proteins). Moreover, phosphorylation at one or more sites of a protein has been involved to alter the conformation of target proteins affecting their functions or interaction with other proteins [<xref ref-type="bibr" rid="scirp.107411-ref27">27</xref>]. Analysis of the Allen Mouse Brain Atlas suggests that at least 260 kinases are expressed in adult mouse brain. The involvement of these kinases has been implicated in learning and memory. These findings support our results as an ERK interacting proteins showed richness in protein kinase domain. Such studies are helpful to understand ERK mediated cell singling pathways including neurodegenerative diseases.</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> ERK interacting proteins and their motifs</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >S.N.</th><th align="center" valign="middle" >NCBI Reference Sequence</th><th align="center" valign="middle" >Gene Name</th><th align="center" valign="middle" >Protein Name</th><th align="center" valign="middle" >No of found domain</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >NP_004433</td><td align="center" valign="middle" >EPHB2</td><td align="center" valign="middle" >Ephrin type-B receptor 2 isoform 2 precursor</td><td align="center" valign="middle" >Total = 9 (ProPat-5, ProPro-4)/motifs</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >NP_620407.1</td><td align="center" valign="middle" >MAPK1</td><td align="center" valign="middle" >Mitogen-activated protein kinase 1</td><td align="center" valign="middle" >Total = 4 (ProPat-3, ProPro-1)</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >NP_060033.3</td><td align="center" valign="middle" >IL17RD</td><td align="center" valign="middle" >Interleukin-17 receptor D precursor</td><td align="center" valign="middle" >Total = 1 (ProPat-none, ProPro-1)</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >NP_001093207.1</td><td align="center" valign="middle" >WDR83</td><td align="center" valign="middle" >WD repeat domain-containing protein 83</td><td align="center" valign="middle" >Total = 3 (ProPat-1, ProPro-2)</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >AAH15221.1</td><td align="center" valign="middle" >TESC</td><td align="center" valign="middle" >Tescalcin</td><td align="center" valign="middle" >Total = 2 (ProPat -1, ProPro-1)</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >AAI36277.1</td><td align="center" valign="middle" >MAP3K4</td><td align="center" valign="middle" >Mitogen-activated protein kinase kinasekinase 4</td><td align="center" valign="middle" >Total = 3 (ProPat-2, ProPro-1)</td></tr><tr><td align="center" valign="middle" >7</td><td align="center" valign="middle" >Q6VAB6.2</td><td align="center" valign="middle" >KSR2</td><td align="center" valign="middle" >Rec Name: Full = Kinase suppressor of Ras 2; Short = hKSR2</td><td align="center" valign="middle" >Total = 4 (ProPat-2, ProPro-2)</td></tr><tr><td align="center" valign="middle" >8</td><td align="center" valign="middle" >EAX07758.1</td><td align="center" valign="middle" >MAP3K6</td><td align="center" valign="middle" >Mitogen-activated protein kinase kinasekinase 6</td><td align="center" valign="middle" >Total = 3 (ProPat-2, ProPro-1)</td></tr><tr><td align="center" valign="middle" >9</td><td align="center" valign="middle" >AAQ89028.1</td><td align="center" valign="middle" >ULBP2</td><td align="center" valign="middle" >UL16 binding protein 2</td><td align="center" valign="middle" >Total = none( ProPat-nil, ProPro-none)</td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >AAK13081.1</td><td align="center" valign="middle" >ULBP1</td><td align="center" valign="middle" >UL16 binding protein 1</td><td align="center" valign="middle" >Total = none (ProPat-none, ProPro-none)</td></tr><tr><td align="center" valign="middle" >11</td><td align="center" valign="middle" >CAG38739.1</td><td align="center" valign="middle" >DUSP14</td><td align="center" valign="middle" >Dual specificity phosphatase 14</td><td align="center" valign="middle" >Total = 3 (ProPat-1, ProPro -2)</td></tr><tr><td align="center" valign="middle" >12</td><td align="center" valign="middle" >BAA34369.1</td><td align="center" valign="middle" >DUSP6</td><td align="center" valign="middle" >dual specificity phosphatase 6</td><td align="center" valign="middle" >Total = 3 (ProPat-none, ProPro-3)</td></tr><tr><td align="center" valign="middle" >13</td><td align="center" valign="middle" >AAI08905.1</td><td align="center" valign="middle" >RHAMM</td><td align="center" valign="middle" >Hyaluronan-mediated motility receptor</td><td align="center" valign="middle" >Total = none (ProPat-nil, ProPro-none)</td></tr><tr><td align="center" valign="middle" >14</td><td align="center" valign="middle" >NP_065789.1</td><td align="center" valign="middle" >KIDINS220</td><td align="center" valign="middle" >Kinase D-interacting substrate of 220 kDa</td><td align="center" valign="middle" >Total = 2 (ProPat-none, ProPro-2)</td></tr><tr><td align="center" valign="middle" >15</td><td align="center" valign="middle" >NP_001136254.1</td><td align="center" valign="middle" >MAGI3</td><td align="center" valign="middle" >Membrane-associated guanylate kinase</td><td align="center" valign="middle" >Total = 6 (ProPat-3, ProPro-3)</td></tr><tr><td align="center" valign="middle" >16</td><td align="center" valign="middle" >CAG46533.1</td><td align="center" valign="middle" >PEA15</td><td align="center" valign="middle" >Phosphoprotein enriched in astrocytes 15</td><td align="center" valign="middle" >Total = 1 (ProPat-none, ProPro-1)</td></tr><tr><td align="center" valign="middle" >17</td><td align="center" valign="middle" >AAH95453.1</td><td align="center" valign="middle" >WARS</td><td align="center" valign="middle" >Tryptophanyl-tRNA synthetase, cytoplasmic</td><td align="center" valign="middle" >Total = 4 (ProPat-3, ProPro-1)</td></tr><tr><td align="center" valign="middle" >18</td><td align="center" valign="middle" >AAH60837.1</td><td align="center" valign="middle" >DUSP9</td><td align="center" valign="middle" >Dual specificity phosphatase 9</td><td align="center" valign="middle" >Total = 3 (ProPat-none, ProPro-3)</td></tr><tr><td align="center" valign="middle" >19</td><td align="center" valign="middle" >NP_005912.1</td><td align="center" valign="middle" >MAP3K1</td><td align="center" valign="middle" >Mitogen-activated protein kinase kinasekinase 1</td><td align="center" valign="middle" >Total = 5 (ProPat-2, ProPro-3)</td></tr><tr><td align="center" valign="middle" >20</td><td align="center" valign="middle" >AAK13083.1</td><td align="center" valign="middle" >ULBP3</td><td align="center" valign="middle" >UL16 binding protein 3</td><td align="center" valign="middle" >Total = none (ProPat -nil, ProPro-none)</td></tr><tr><td align="center" valign="middle" >21</td><td align="center" valign="middle" >NP_067004.3</td><td align="center" valign="middle" >SLAMF7</td><td align="center" valign="middle" >SLAM family member 7 isoform a precursor</td><td align="center" valign="middle" >Total = 1 (ProPat-none, ProPro-1)</td></tr><tr><td align="center" valign="middle" >22</td><td align="center" valign="middle" >NP_002410.1</td><td align="center" valign="middle" >MAP3K11</td><td align="center" valign="middle" >Mitogen-activated protein kinase kinasekinase 11</td><td align="center" valign="middle" >Total = 4 (ProPat-2, ProPro-2)</td></tr></tbody></table></table-wrap></sec><sec id="s4"><title>4. Conclusion</title><p>Majority of the ERK interacting proteins are rich in random coil and alpha helix % (<xref ref-type="table" rid="table2">Table 2</xref>). Further, most of interacting proteins have serine/threonine kinases active site signature and protein kinase ATP binding region. In addition, few have commonly dual specificity protein phosphatase family and tyrosine specific protein phosphatase domains (<xref ref-type="table" rid="table3">Table 3</xref>). Such study may be helpful to design engineered molecules for regulating ERK dependent pathways in disease condition.</p></sec><sec id="s5"><title>Acknowledgements</title><p>VP acknowledges Science and Engineering Research Board (SERB), Government of India for providing financial support (SB/YS/LS-200/2013). KK acknowledges SERB for Junior Research Fellowship and Indian Council of Medical Research (ICMR) for Senior Research Fellowship (Letter No. 45/72/l 8-PHA/BMS/OL).</p></sec><sec id="s6"><title>Conflicts of Interest</title><p>Authors declare no conflict of interest in any issue.</p></sec><sec id="s7"><title>Cite this paper</title><p>Khuleshwari, K. and Vijay, P. (2021) Identification of Secondary Structure of Extracellular Signal Regulated Kinase (ERK) Interacting Proteins and Their Domain: An in Silico Study. World Journal of Neuroscience, 11, 67-89. https://doi.org/10.4236/wjns.2021.111007</p></sec></body><back><ref-list><title>References</title><ref id="scirp.107411-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Tang, S.J., Reis, G., Kang, H., Gingras, A., Sonenberg, N. and Schuman, E.M. (2002) A Rapamycin-Sensitive Signaling Pathway Contributes to Long-Term Synaptic Plasticity in the Hippocampus. Proceedings of the National Academy of Sciences of the United States of America, 99, 467-472. https://doi.org/10.1073/pnas.012605299</mixed-citation></ref><ref id="scirp.107411-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Cammalleri, M., Lutjens, R., Berton, F., King, R.A., Simpson, C., Francesconi, W., et al. (2003) Time-Restricted Role for Dendritic Activation of the mTOR-p70S6K Pathway in the Induction of Late-Phase Long-Term Potentiation in the CA1. Proceedings of the National Academy of Sciences of the United States of America, 100, 14368-14373. https://doi.org/10.1073/pnas.2336098100</mixed-citation></ref><ref id="scirp.107411-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Bekinschtein, P., Katche, C., Slipczuk, L.N., Igaz, M.L., Cammarota, M., Izquierdo, I., et al. (2007) TOR Signaling in the Hippocampus Is Necessary for Memory Formation. Neurobiology of Learning and Memory, 87, 303-307.https://doi.org/10.1016/j.nlm.2006.08.007</mixed-citation></ref><ref id="scirp.107411-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Lu, Y., Christian, K. and Lu, B. (2008) BDNF: A Key Regulator for Protein Synthesis-Dependent LTP and Long-Term Memory? Neurobiology of Learning and Memory, 89, 312-323. https://doi.org/10.1016/j.nlm.2007.08.018</mixed-citation></ref><ref id="scirp.107411-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Dudai, Y. and Eisenberg, M. (2004) Rites of Passage of the Engram: Reconsolidation and the Lingering Consolidation Hypothesis. Neuron, 44, 93-100.https://doi.org/10.1016/j.neuron.2004.09.003</mixed-citation></ref><ref id="scirp.107411-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Takei, N., Inamura, N., Kawamura, M., Namba, H., Hara, K., Yonezawa, K., et al. (2004) Brain-Derived Neurotrophic Factor Induces Mammalian Target of Rapamycin-Dependent Local Activation of Translation Machinery and Protein Synthesis in Neuronal Dendrites. Journal of Neuroscience, 24, 9760-9769.https://doi.org/10.1523/JNEUROSCI.1427-04.2004</mixed-citation></ref><ref id="scirp.107411-ref7"><label>7</label><mixed-citation publication-type="book" xlink:type="simple">Giese, K.P. (2012) Long-Term Potentiation and Memory. In: Giese, K.P., Ed., Memory Mechanism and Health Disease: Mechanistic Basis of Memory, World Scientific, Singapore, 1-17. https://doi.org/10.1142/9789814366700_0001</mixed-citation></ref><ref id="scirp.107411-ref8"><label>8</label><mixed-citation publication-type="book" xlink:type="simple">Stewart, M.G. and Popov, V.I. (2012) Structural Synaptic and Dendritic Spine Plasticity in the Hippocampus. In: Giese, K.P., Ed., Memory Mechanisms in Health and Disease, World Scientific Publishing, Singapore, 19-52.https://doi.org/10.1142/9789814366700_0002</mixed-citation></ref><ref id="scirp.107411-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Papoutsi, A., Sidiropoulou, K., Cutsuridis, V. and Poirazi, P. (2013) Induction and Modulation of Persistent Activity in a Layer V PFC Microcircuit Model. Frontiers of Neural Circuits, 7, 161. https://doi.org/10.3389/fncir.2013.00161</mixed-citation></ref><ref id="scirp.107411-ref10"><label>10</label><mixed-citation publication-type="book" xlink:type="simple">Stone, S.S.D., Frankland, P.W. (2012) Adult Hippocampal Neurogenesis and Memory. In: Giese, K.P., Ed., Memory Mechanisms in Health and Disease, World Scientific Publishing, Singapore, 81-146. https://doi.org/10.1142/9789814366700_0004</mixed-citation></ref><ref id="scirp.107411-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Kim, S.Y., Hwang, G.S., Han, H. and Cho, M. (2011) Phosphorylation Alters Backbone Conformational Preferences of Serine and Threonine Peptides. Proteins: Structure, Function, and Bioinformatics, 79, 3155-3165. https://doi.org/10.1002/prot.23148</mixed-citation></ref><ref id="scirp.107411-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Costa-Mattioli, M., Sossin, W.S., Klann, E. and Sonenberg, N. (2009) Translational Control of Long-Lasting Synaptic Plasticity and Memory. Neuron, 61, 10-26.https://doi.org/10.1016/j.neuron.2008.10.055</mixed-citation></ref><ref id="scirp.107411-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Slipczuk, L., Bekinschtein, P., Katche, C., Cammarota, M.I., Izquierdo, I. and Medina, J.H. (2009). BDNF Activates mTOR to Regulate GluR1 Expression Required for Memory Formation. PLoS ONE, 4, e6007. https://doi.org/10.1371/journal.pone.0006007</mixed-citation></ref><ref id="scirp.107411-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Ruvinsky, I. and Meyuhas, O. (2006) Ribosomal Protein S6 Phosphorylation: From Protein Synthesis to Cell Size. Trends in Biochemical Sciences, 31, 342-348. https://doi.org/10.1016/j.tibs.2006.04.003</mixed-citation></ref><ref id="scirp.107411-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Hay, N. and Sonenberg N. (2004) Upstream and Downstream of mTOR. Genes and Development, 18, 1926-1945. https://doi.org/10.1101/gad.1212704</mixed-citation></ref><ref id="scirp.107411-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">McClung, C.A. and Nestler, E.J. (2008) Neuroplasticity Mediated by Altered Gene Expression. Neuropsychopharmacology, 33, 3-17. https://doi.org/10.1038/sj.npp.1301544</mixed-citation></ref><ref id="scirp.107411-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Taubenfeld, M.S., Milekic, H.M., Monti, B. and Alberini, M.C. (2001) The Consolidation of New but Not Reactivated Memory Requires Hippocampal C/EBPβ. Nature Neuroscience, 4, 813-818. https://doi.org/10.1038/90520</mixed-citation></ref><ref id="scirp.107411-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Goelet, P., Castellucci, F.V., Schacher, S. and Kandel, R.E. (1986) The Long and the Short of Long-Term Memory—A Molecular Framework. Nature, 322, 419-422.https://doi.org/10.1038/322419a0</mixed-citation></ref><ref id="scirp.107411-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Kohn, J.E., Millett, I.S., Jacob, J., Zagrovic, B., Zagrovic, B., Dillon, T.M., Cingel, N., et al. (2004) Random-Coil Behavior and the Dimensions of Chemically Unfolded Proteins. Proceedings of the National Academy of Sciences of the United States of America, 101, 12491-112496. https://doi.org/10.1073/pnas.0403643101</mixed-citation></ref><ref id="scirp.107411-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Sigrist, C.J., Cerutti, L., Hulo, N., Gattiker, A., Falquet, L., Pagni, M., et al. (2002) PROSITE: A Documented Database Using Patterns and Profiles as Motif Descriptors. Briefings in Bioinformatics, 3, 265-274. https://doi.org/10.1093/bib/3.3.265</mixed-citation></ref><ref id="scirp.107411-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Rajasekaran, S.,Balla, S., Gradie, P., Gryk, M.R., Kadaveru, K., Kundeti, V., et al. (2009) Minimotif Miner 2nd Release: A Database and Web System for Motif Search. Nucleic Acid Research, 37, D185-D190. https://doi.org/10.1093/nar/gkn865</mixed-citation></ref><ref id="scirp.107411-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Kleywegt, G.J. (1999) Recognition of Spatial Motifs in Protein Structures. Journal of Molecular Biology, 285, 1887-1897. https://doi.org/10.1006/jmbi.1998.2393</mixed-citation></ref><ref id="scirp.107411-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Taylor, S.S. and Radzio-Andzelm, E. (1994) Three Protein Kinase Structures Define a Common Motif. Structure, 2, 345-355. https://doi.org/10.1016/S0969-2126(00)00036-8</mixed-citation></ref><ref id="scirp.107411-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Ebisuya, M., Kondoh, K. and Nishida, E. (2005) The Duration, Magnitude and Compartmentalization of ERK MAP Kinase Activity: Mechanisms for Providing Signaling Specificity. Journal of Cell Science, 118, 2997-3002.https://doi.org/10.1242/jcs.02505</mixed-citation></ref><ref id="scirp.107411-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Kurrey, K. and Paramanik, V. (2018) Identification and Physiochemical Analysis of ERK Interacting Proteins Using Bio-Computational Tools. World Journal of Neuroscience, 8, 303-313. https://doi.org/10.4236/wjns.2018.82024</mixed-citation></ref><ref id="scirp.107411-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Fantz, D.A., Jacobs, D., Glossip, D. and Kornfeld, K. (2001) Docking Sites on Substrate Proteins Direct Extracellular Signal Regulated Kinase to Phosphorylate Specific Residues. Journal of Biological Chemistry, 276, 27256-27265.https://doi.org/10.1074/jbc.M102512200</mixed-citation></ref><ref id="scirp.107411-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Biondi, M.R. and Nebreda, R.A. (2003) Signalling Specificity of Ser/Thr Protein Kinases through Docking-Site-Mediated Interactions. Biochemical Journal, 372, 1-13.https://doi.org/10.1042/bj20021641</mixed-citation></ref></ref-list></back></article>